These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32810412)

  • 21. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
    Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
    Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
    Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
    Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the Relationship between FEV
    Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
    Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
    Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
    Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations.
    Sequeiros IM; Jarad NA
    Chron Respir Dis; 2012; 9(4):213-20. PubMed ID: 22637747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Clinical Association between
    O'Dea AL; Feng R; Glaser LJ; Kubrak C; Rubenstein RC; Dorgan DJ; Hadjiliadis D; Kawut SM; Hong G
    Ann Am Thorac Soc; 2023 Jul; 20(7):984-992. PubMed ID: 36800434
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    Nguyen D; Emond MJ; Mayer-Hamblett N; Saiman L; Marshall BC; Burns JL
    Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
    Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
    BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Ryan G; Jahnke N; Remmington T
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations.
    Faino AV; Hoffman LR; Gibson RL; Kronman MP; Nichols DP; Rosenfeld M; Cogen JD
    J Cyst Fibros; 2023 Jul; 22(4):630-635. PubMed ID: 36849332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
    Sanders DB; Zhao Q; Li Z; Farrell PM
    Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients.
    Avedissian SN; Rhodes NJ; Ng TMH; Rao AP; Beringer PM
    Pharmacotherapy; 2019 Jun; 39(6):718-723. PubMed ID: 31045258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
    Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
    J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Pasta DJ; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):763-9. PubMed ID: 25754096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Azithromycin therapy in cystic fibrosis].
    Máiz Carro L; Cantón Moreno R
    Med Clin (Barc); 2004 Mar; 122(8):311-6. PubMed ID: 15030744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.